TL;DR: Selank and Semax are short synthetic peptides from Russian research institutes in the 1990s, engineered as stabilized versions of natural molecules — Selank from tuftsin, Semax from an ACTH fragment. Selank is studied mainly for anxiety-related effects, Semax for cognition and neuroprotection, and both converge on raising BDNF. Both are registered medicines in Russia and approved nowhere in the West. Supplied for research use only.
Where They Came From
Both peptides emerged from Russian research institutes in the 1990s, and both follow the same design strategy: take a natural molecule with useful activity but poor stability, and modify it so it survives long enough to act.
Selank derives from tuftsin, a short immune-modulating peptide. Semax derives from a fragment of ACTH, the hormone that triggers cortisol release. In each case the modification preserved the activity of interest while extending metabolic half-life — and in Semax's case, deliberately removed the hormonal activity that would otherwise come along with it.
Selank: The Anxiety Angle
Published preclinical work reports anxiety-reducing effects in animal models. The proposed mechanisms involve the GABA system — the brain's principal inhibitory signalling network — along with serotonin signalling and shifts in BDNF.
What distinguishes Selank in the research literature is largely what it is not reported to do. Benzodiazepines act on the GABA system and carry well-documented sedation, dependence, and memory costs. Selank's reported profile lacks that pattern.
Two caveats belong with that. Most of this is animal-model work, and absence of a reported effect is weaker evidence than demonstration of its absence — particularly where long-term studies are sparse.
Semax: BDNF and Cognition
Semax is a fragment of ACTH modified to drop the cortisol-triggering activity while retaining central nervous system effects. That separation is the clever part of the design: ACTH's hormonal cascade and its neurological effects were decoupled.
Its most consistent published finding is elevation of BDNF and NGF (nerve growth factor) in target brain regions, with the hippocampus — the structure most associated with memory formation — receiving the most attention.
In Russia, Semax has been used clinically for decades in contexts including stroke recovery and cognitive disorders.
Side by Side
| Selank | Semax | |
|---|---|---|
| Derived from | Tuftsin (immune peptide) | ACTH fragment |
| Primary research focus | Anxiety, stress response | Cognition, neuroprotection |
| Reported mechanisms | GABA, serotonin, BDNF | BDNF, NGF, hippocampal signalling |
| Common study route | Intranasal | Intranasal |
The Shared BDNF Thread
The mechanism both peptides converge on is worth understanding on its own. BDNF — brain-derived neurotrophic factor — is a growth factor supporting neuron survival, growth, and synaptic plasticity, the capacity of connections between neurons to strengthen and reorganize.
BDNF is also raised by exercise, sleep, and learning itself, which is part of why it attracts so much interest as a target: it sits at a convergence point for things already known to support brain function. That said, "raises BDNF" is a mechanistic observation, not a demonstrated cognitive outcome, and the distance between those two claims is where most nootropic overstatement lives.
Why Intranasal Delivery
Both are commonly studied via intranasal administration, for a practical reason. The nasal mucosa offers a relatively direct route to the central nervous system, bypassing both the digestive tract and the liver's first-pass metabolism.
For peptides this matters more than it would for small molecules. A short peptide taken orally is largely digested as protein before it can act. Intranasal delivery sidesteps that problem, which is why it dominates the published cognitive literature for this class.
Reading the Evidence Honestly
This class sits in an unusual evidentiary position, and it is worth stating plainly rather than glossing.
Both compounds are registered medicines in Russia with decades of clinical use behind them. Neither is approved in the West, and the supporting literature is largely published in Russian-language journals with limited independent replication.
Neither the dismissive reading nor the credulous one is right. "Approved in Russia" is not equivalent to FDA or EMA approval, and treating it as such overstates the case. But decades of clinical use is also not nothing, and dismissing the entire literature because of its language of publication would be its own error. The accurate description is: a real evidence base, less accessible and less replicated than Western-developed compounds, and correspondingly harder to evaluate.
Handling and Sourcing
Both ship lyophilized and are reconstituted with bacteriostatic water, then refrigerated. Our peptide storage guide covers stability and freeze-thaw considerations, and the reconstitution calculator handles the concentration math.
For current stock, forms, and purity testing, see our Selank Canada page and the Canadian research peptides overview. For an adjacent cognitive research compound, see our Dihexa overview.
For Research Use Only
Everything above describes laboratory and clinical research. Selank and Semax are not approved therapeutics in Canada or the United States. Helix North supplies them for research applications only — not for human or animal consumption, and nothing here constitutes medical, dosing, or clinical guidance.
